Court rules against IMS, SDI on NH Rx data ban

Share this article:
A federal appeals court has overturned a lower court's injunction of New Hampshire's ban on commercial provision of prescription data, arguing that such restrictions do not constitute an abridgment of free speech. 

Writing for the US Court of Appeals for the First Circuit, Judge Bruce Selya said: “We are not persuaded that the regulated data transfers embody restrictions on protected speech.” 

“Unlike stereotypical commercial speech,” he added, “new information is not filtered into the marketplace with the possibility of stimulating a better informed consumer choice (after all, physicians already know their own prescribing histories) and the societal benefits flowing from the prohibited transactions pale in comparison to the negative externalities produced.”  

Two data companies, IMS Health and Verispan (now part of SDI), sued for an injunction against a New Hampshire law prohibiting the sale of prescribing data for use in pharmaceutical detailing, arguing that it violated their First Amendment rights. A US district court agreed with them. 

The decision overturns the district court injunction and opens the door to similar laws already on the books in Vermont and Maine and pending in two dozen more states. 

In a joint statement, the data companies expressed disappointment with the decision and said they were evaluating potential next steps. 

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?